Dr. Oh on the Use of Abiraterone and Docetaxel in mCRPC

William K. Oh, MD
Published: Friday, Dec 15, 2017



William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, discusses the use of abiraterone acetate (Zytiga) and docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC).

The use of abiraterone and docetaxel was established in mCRPC, and there are many conversations about combinations. There are currently no clear answers to these questions.
 


William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, discusses the use of abiraterone acetate (Zytiga) and docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC).

The use of abiraterone and docetaxel was established in mCRPC, and there are many conversations about combinations. There are currently no clear answers to these questions.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x